Urothelial Cancer | Norton Healthcare

Indication: Urothelial Cancer

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy

Locally advanced or metastatic

Sub-indication: Locally Advanced or Metastatic Urothelial Cancer with previous Tx with CPI.

Line of Therapy: 2nd line, must have received CPI in locally advanced or metastatic setting. Cohort 1: previous tx with platinum in adjuvant or neoadjuvant setting. Cohort 2: Platinum naive or cisplatin ineligible due to ECOG 2, Hearing loss Grade 2, or CRCL < 60 ml/min.

Drug Study

Principal Investigator: Chandler Park, M.D.

Sponsor: Seattle Genetics, Inc

Learn more at ClinicalTrials.gov

Email for more information: GU-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.